Bloom Burton reissued their buy rating on shares of Centric Health (TSE:CRX – Get Rating) in a report published on Tuesday, PriceTargets.com reports. Bloom Burton also issued estimates for Centric Health’s Q2 2023 earnings at ($0.02) EPS, Q3 2023 earnings at ($0.01) EPS, Q4 2023 earnings at $0.00 EPS, FY2023 earnings at ($0.07) EPS, FY2024 earnings at $0.05 EPS and FY2025 earnings at $0.17 EPS.
Separately, Leede Jones Gab reiterated a buy rating on shares of Centric Health in a research note on Friday, March 10th.
Centric Health Stock Performance
Centric Health (TSE:CRX – Get Rating) last announced its quarterly earnings results on Thursday, March 9th. The company reported C($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.06) by C($0.04). The firm had revenue of C$94.32 million for the quarter, compared to the consensus estimate of C$94.73 million.
Read More
Receive News & Ratings for Centric Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Centric Health and related companies with MarketBeat.com’s FREE daily email newsletter.